Lantheus Holdings Inc(LNTH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:19 AM ET (Korea 9/11 20:19)
Full metrics table
| Index | RUT | P/E | 24.26 | EPS (ttm) | 4.14 | Insider Own | 3.43% | Shs Outstand | 65.3M | Perf Week | -0.42% |
| Market Cap | 6.56B | Forward P/E | 15.68 | EPS next Y | 18.84% | Insider Trans | -11.47% | Shs Float | 63.0M | Perf Month | -0.29% |
| Enterprise Value | 6.59B | PEG | 1.75 | EPS next Q | 1.26 | Inst Own | 116.58% | Short Float | 8.13% | Perf Quarter | 0.15% |
| Income | 0.28B | P/S | 4.21 | EPS this Y | -11.37% | Inst Trans | 2.37% | Short Ratio | 3.82 | Perf Half Y | 21.48% |
| Sales | 1.56B | P/B | 4.99 | EPS next 5Y | 8.96% | ROA | 12.15% | Short Interest | 5.12M | Perf YTD | 50.85% |
| Book/sh | 20.1 | P/C | 11.05 | EPS past 3/5Y | 104.81% - | ROE | 22.21% | 52W High | -10.25% ($111.86) | Perf Year | 91.22% |
| Cash/sh | 9.09 | P/FCF | 16.9 | Sales past 3/5Y | 18.13% 35.35% | ROIC | 14.22% | 52W Low | 102.11% ($49.67) | Perf 3Y | 51.19% |
| Dividend Est. | - | EV/EBITDA | 16.84 | EPS Y/Y TTM | 7.38% | Gross Margin | 60.14% | Volatility(W/M) | 0.41% 0.49% | Perf 5Y | 286.71% |
| Dividend TTM | - | EV/Sales | 4.23 | Sales Y/Y TTM | 2.35% | Oper. Margin | 19.45% | ATR (14) | 0.96 | Perf 10Y | 1249.33% |
| Dividend Ex-Date | - | Quick Ratio | 2.89 | EPS Q/Q | -0.79% | Profit Margin | 17.69% | RSI (14) | 44.31 | Recom | 2.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.06 | Sales Q/Q | 2.68% | SMA20 | -0.29% ($100.68) | Beta | -0.06 | Target Price | $106.84 |
| Payout | - | Debt/Eq | 0.48 | Earnings | 2026/8/6 | SMA50 | -2.09% ($102.53) | Rel Volume | 0.46 | Prev Close | $100.7 |
| Employees | 1193 | LT Debt/Eq | 0.48 | EPS/Sales Surpr. | 18.9% 6.87% | SMA200 | 18.21% ($84.93) | Avg Volume(3M) | 1.34M | Price | $100.39 |
| IPO | 2015/6/25 | Option/Short | Yes/Yes | Trades | 8218 | Volume | 613,154 | Change | -0.31% |
Company
LNTH is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🔬 A U.S. healthcare company that develops and sells radiopharmaceuticals for diagnosis and treatment, as well as imaging contrast agents. With a core focus on radiopharmaceuticals used in prostate cancer diagnostic imaging and ultrasound contrast agents, the company is also expanding into therapeutic radiopharmaceuticals, making it a pharmaceutical stock whose performance is closely tied to revenue from its key products and pipeline.
Over the past 1 year, on the higher side
10% below its 1-year high.
LNTH makes money exceptionally well
19.45% of revenue is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -11.4% this year.
Tap to view numbers
The price looks about right
Trading at 24.3 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Would have changed by +51.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 116.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
NEWZ 0.04%
GRPM 0.04%
ZIG 0.04%
XHE 0.02%
FSGS 0.01%It ranks #4 in the industry
Based on market cap of $7B.
LNTH $7B PER 24.3
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is LNTH?
LNTH belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of LNTH?
The market cap of LNTH is approximately $6.6B, ranking 1,185 within its sector.
What is the P/E ratio of LNTH?
LNTH has a P/E ratio of approximately 24.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for LNTH?
LNTH has recorded a 52-week high of $111.86 and a low of $49.67.
